NCT02943733 is a Phase 1 clinical trial of TAS-102 in Neuroendocrine Tumors, sponsored by University of Wisconsin, Madison.

Who is sponsoring NCT02943733?

NCT02943733 is sponsored by University of Wisconsin, Madison.

What drugs are being tested in NCT02943733?

Interventions in NCT02943733: TAS-102, Temozolomide, Filgrastim, Pegfilgrastim.

What condition does NCT02943733 study?

NCT02943733 studies Neuroendocrine Tumors, Neoplasms, Cancer, Tumors.

Is NCT02943733 still recruiting?

NCT02943733 is currently terminated. Last updated 23 September 2022.

Last reviewed 2022-09-23 · How we verify

NCT02943733

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

Terminated Phase 1 Last updated 23 September 2022

What this trial tests

Phase 1 trial testing TAS-102 in Neuroendocrine Tumors in 18 participants. Terminated before completion.

Timeline

22 August 2017

Primary endpoint
7 November 2020

31 January 2022

Quick facts

Lead sponsor	University of Wisconsin, Madison
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	22 August 2017
Primary completion	7 November 2020
Estimated completion	31 January 2022
Sites	1 location across United States

Drugs / interventions tested

TAS-102
Temozolomide (temozolomide) — full drug profile →
Filgrastim — full drug profile →
Pegfilgrastim (PEGFILGRASTIM) — full drug profile →

Conditions studied

Neuroendocrine Tumors — all drugs for Neuroendocrine Tumors →
Neoplasms — all drugs for Neoplasms →
Cancer — all drugs for Cancer →
Tumors — all drugs for Tumors →

Sponsor

University of Wisconsin, Madison

Who can join

18 and older, any sex, with Neuroendocrine Tumors or Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to establish maximum tolerated doses/recommended phase 2 dose (RP2D) of temozolomide (TMZ) and TAS-102 when these agents are used in combination and to evaluate the safety profile of this drug combination.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of TAS-102

Trials testing the same drug.

NCT07196345 — TAS-102 Plus Radiotherapy in Elderly ESCC · Phase 1, PHASE2 · not yet recruiting
NCT07116577 — Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC · Phase 2 · not yet recruiting
NCT06346392 — AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic · Phase 3 · recruiting
NCT05481463 — Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer · Phase 2 · completed
NCT05600309 — A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated · Phase 3 · completed

Other recruiting trials for Neuroendocrine Tumors

Currently open trials in the same condition.

NCT07404176 — Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocr · Phase 2 · recruiting
NCT07314164 — Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment · recruiting
NCT07272512 — Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms · Phase 4 · recruiting
NCT06735560 — Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN · NA · recruiting
NCT06889493 — SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Dif · Phase 1 · recruiting

Other University of Wisconsin, Madison trials

Trials by the same sponsor.

NCT07440004 — Testing a Digital Mindfulness Program to Support People Experiencing Suicidal Thoughts · Phase 1 · recruiting
NCT07278466 — The COMParing App Support Strategies Study · NA · recruiting
NCT07475104 — Redesigning Surgical Care for Patients in Wisconsin · NA · enrolling by invitation
NCT07470723 — The ORIGIN-FH Study · NA · recruiting
NCT06975657 — Well-being Skills for Reentry · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02943733 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Wisconsin, Madison
Last refreshed: 23 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02943733.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing